{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:28:59Z","timestamp":1785828539570,"version":"3.56.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["UL1 TR000445"],"award-info":[{"award-number":["UL1 TR000445"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008323","name":"Cumberland Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ahj.2020.10.071","type":"journal-article","created":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T23:41:49Z","timestamp":1604274109000},"page":"116-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial"],"prefix":"10.1016","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-0146","authenticated-orcid":false,"given":"Zachary L","family":"Cox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Aaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel A","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Thomas McRae","family":"III","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth T","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Lindsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank E Harrell","family":"Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy A","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen F","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B","family":"Stubblefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Lindenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2020.10.071_bib0001","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.jacc.2019.08.001","article-title":"2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee.","volume":"74","author":"Hollenberg","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahj.2020.10.071_bib0002","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ahj.2020.10.071_bib0003","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardio-renal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.10.071_bib0004","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jchf.2019.01.007","article-title":"Natriuretic response is highly variable and associated with 6-month survival: insights from the ROSE-AHF TRIAL","volume":"7","author":"Hodson","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2020.10.071_bib0005","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ehf2.12368","article-title":"Early urine electrolyte patterns in patients with acute heart failure","volume":"6","author":"Collins","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ahj.2020.10.071_bib0006","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ahj.2018.01.013","article-title":"First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization","volume":"203","author":"Luk","year":"2018","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ahj.2020.10.071_bib0007","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijcard.2017.08.053","article-title":"Long-term prognostic significance of urinary sodium concentration in patients with acute heart failure","volume":"254","author":"Honda","year":"2018","journal-title":"Int. J. Cardiol"},{"issue":"11","key":"10.1016\/j.ahj.2020.10.071_bib0008","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/ejhf.1492","article-title":"Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry","author":"Chioncel","year":"2019","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.ahj.2020.10.071_bib0009","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1161\/CIRCHEARTFAILURE.114.001957","volume":"8","author":"Lala","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ahj.2020.10.071_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009149","article-title":"Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: a propensity analysis","volume":"7","author":"Brisco-Bacik","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.ahj.2020.10.071_bib0011","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jchf.2019.09.012","article-title":"Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial","author":"Cox","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2020.10.071_bib0012","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/j.jacc.2004.01.041","article-title":"Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge","volume":"43","author":"Butler","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.10.071_bib0013","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial","volume":"43","author":"Gattis","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.10.071_bib0014","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ahj.2013.03.007","article-title":"Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure","volume":"165","author":"Curtis","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2020.10.071_bib0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cardfail.2013.11.006","article-title":"Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation","volume":"20","author":"Eapen","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2020.10.071_bib0016","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.2337\/dc20-S015","article-title":"Diabetes care in the hospital: Standards of Medical Care in Diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2020.10.071_bib0017","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2020.10.071_bib0018","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jchf.2018.11.013","article-title":"Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists","volume":"7","author":"Vardeny","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2020.10.071_bib0019","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s13300-017-0277-0","article-title":"Practical approach to initiating SGLT2 inhibitors in type 2 diabetes","volume":"8","author":"Gomez-Peralta","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ahj.2020.10.071_bib0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jchf.2019.12.010","article-title":"Natriuretic peptides as inclusion criteria in clinical trials: a JACC: heart failure position paper","volume":"8","author":"Ibrahim","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2020.10.071_bib0021","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.10.071_bib0022","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2020.10.071_bib0023","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","article-title":"Diuretic therapy for patients with heart failure: JACC state-of-the-art review","volume":"75","author":"Felker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahj.2020.10.071_bib0024","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cardfail.2011.12.009","article-title":"Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network","volume":"18","author":"Bart","year":"2012","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ahj.2020.10.071_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.ahj.2020.10.071_bib0026","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2307\/2983064","article-title":"Spurious correlation and the fallacy of the ratio standard revisited","volume":"156","author":"Kronmal","year":"1993","journal-title":"J Roy Stat Soc A Sta"},{"key":"10.1016\/j.ahj.2020.10.071_bib0027","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002370","article-title":"Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure","volume":"9","author":"Testani","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ahj.2020.10.071_bib0028","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCHEARTFAILURE.113.000895","article-title":"Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure","volume":"7","author":"Testani","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ahj.2020.10.071_bib0029","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/ejhf.757","article-title":"Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure","volume":"19","author":"Ter Maaten","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahj.2020.10.071_bib0030","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.170","article-title":"Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome\u2013an analysis from RELAX-AHF","volume":"16","author":"Voors","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahj.2020.10.071_bib0031","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ahj.2015.05.003","article-title":"Diuretic response in acute heart failure-an analysis from ASCEND-HF","volume":"170","author":"Ter Maaten","year":"2015","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ahj.2020.10.071_bib0032","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/eurheartj\/ehu065","article-title":"Diuretic response in acute heart failure: clinical characteristics and prognostic significance","volume":"35","author":"Valente","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ahj.2020.10.071_bib0033","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijcard.2016.09.005","article-title":"Different diuretic dose and response in acute decompensated heart failure: clinical characteristics and prognostic significance","volume":"224","author":"Palazzuoli","year":"2016","journal-title":"Int. J. Cardiol"},{"issue":"6","key":"10.1016\/j.ahj.2020.10.071_bib0034","doi-asserted-by":"crossref","first-page":"e002845","DOI":"10.1161\/CIRCHEARTFAILURE.115.002845","article-title":"Combining diuretic response and hemoconcentration to predict rehospitalization after admission for acute heart failure","volume":"9","author":"Ter Maaten","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10.1016\/j.ahj.2020.10.071_bib0035","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","author":"Damman","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahj.2020.10.071_bib0036","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ahj.2020.10.071_bib0037","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10741-019-09851-9","article-title":"Loop diuretic resistance complicating acute heart failure","author":"Cox","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ahj.2020.10.071_bib0038","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2010.06.034","article-title":"Combination of loop diuretics with thiazide-type diuretics in heart failure","volume":"56","author":"Jentzer","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahj.2020.10.071_bib0039","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jacc.2012.11.054","article-title":"Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort","volume":"61","author":"Mebazaa","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahj.2020.10.071_bib0040","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/CIRCULATIONAHA.108.821843","article-title":"Elevated admission glucose and mortality in elderly patients hospitalized with heart failure","volume":"119","author":"Kosiborod","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.10.071_bib0041","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2213-8587(16)30402-8","article-title":"Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial","volume":"5","author":"Pasquel","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ahj.2020.10.071_bib0042","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11892-019-1184-8","article-title":"Debate on insulin vs non-insulin use in the hospital setting-is it time to revise the guidelines for the management of inpatient diabetes","volume":"19","author":"Pasquel","year":"2019","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.ahj.2020.10.071_bib0043","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.2337\/dc13-0277","article-title":"Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study","volume":"36","author":"Umpierrez","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2020.10.071_bib0044","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijcard.2019.07.069","article-title":"Change in admission blood glucose from chronic glycemic status in acute heart failure hospitalization and 30-day outcomes: a retrospective analysis","volume":"299","author":"Cox","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ahj.2020.10.071_sbref0045","doi-asserted-by":"crossref","DOI":"10.1111\/jcpt.13107","article-title":"The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: is the risk worth taking","author":"Koufakis","year":"2020","journal-title":"J Clin Pharm Ther"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320303574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320303574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:44:03Z","timestamp":1777376643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870320303574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":45,"alternative-id":["S0002870320303574"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.10.071","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.10.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}